Showing 2501-2510 of 3315 results for "".
- FDA Approves Bausch + Lomb's enVista Envy Full Range of Vision IOLhttps://modernod.com/news/bausch-lomb-announces-fda-approval-of-envista-envy-full-range-of-vision-iol/2482482/Bausch + Lomb announced that the FDA has approved the enVista Envy full range of vision IOL. The new lens is built on the enVista IOL platform and is designed to offer patients a continuous range of vision while providing excellent tolerance for dysphotopsia.
- Ophthalmic Drug Delivery Summit to Convene in San Franciscohttps://modernod.com/news/ophthalmic-drug-delivery-summit-to-convene-in-san-francisco/2482481/In January, over 60 world-leading specialists in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit, an industry-focused event dedicated to enhancing the effectiveness, durability, and minimally invasive nature of retinal drug delivery.</
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300
- Nanoscope Therapeutics Plans to Submit BLA for Gene Therapy to Treat RPhttps://modernod.com/news/nanoscope-therapeutics-plans-to-submit-bla-for-gene-therapy-to-treat-retinitis-pigmentosa/2482476/Nanoscope Therapeutics has announced a successful meeting with the FDA regarding its lead clinical program, MCO-010, for the treatment of retinitis pigmentosa (RP). Following regulatory feedback from the FDA, the company plans to initiate a rolling submission of its biologics license ap
- New Study Unveils How Immune Cells Defend the Eye Against Inflammationhttps://modernod.com/news/new-study-unveils-how-immune-cells-defend-the-eye-against-inflammation/2482470/In a new study, researchers led by Sue Menko, PhD, of Thomas Jefferson University, have revealed how immune cells play a critical role in resolving inflammation on the surface of the eye’s lens. Published in The American Journal of
- Bausch + Lomb Launches Opal Digital Marketplace in the UShttps://modernod.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/Bausch + Lomb announced the US launch of Opal, a new digital e-commerce marketplace designed to enhance efficiency for eye care practices while improving the patient experience. The platform provides a streamlined and user-friendly ordering process for Bausch + Lomb’s contact lens
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri
- Aviceda Completes Enrollment for Phase 2b SIGLEC Study for Geographic Atrophy Treatmenthttps://modernod.com/news/aviceda-completes-enrollment-for-phase-2b-siglec-study-for-geographic-atrophy-treatment/2482456/Aviceda Therapeutics announced the completion of patient enrollment for its phase 2b SIGLEC study. The trial is comparing the safety and efficacy of the company's lead candidate, AVD-104, with avacincaptad pegol (marketed as Izervay) for the treatment of geographic atrophy (GA) secondary to a
- Neuro-Optometric Rehabilitation Association Appoints Barbara Barclay as New Executive Directorhttps://modernod.com/news/neuro-optometric-rehabilitation-association-appoints-barbara-barclay-as-new-executive-director/2482455/The Neuro-Optometric Rehabilitation Association, International (NORA), has announced the appointment of Barbara Barclay as its new executive director, effective October 1. Ms. Barclay, an expert in eye-tracking technology and health tech, brings more than 30 years of leadership experience, i
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the